Skip to main content

Table 1 Demographic and clinical characteristics of patients diagnosed with ADCs and NADCs

From: Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining cancers in HIV-infected individuals

 

All ADCs

All NADCs

P value*

Infection-related NADC

Infection-unrelated NADC

Mixeda

(n = 105)

(n = 320)

    

Hodgkin

Anal

Liver

Lung

Prostate

Oral

(n = 18)

(n = 20)

(n = 29)

(n = 60)

(n = 47)

(n = 32)

Characteristics

N (%) or Median (IQR)

  

N (%) or Median (IQR)

Year of diagnosis

         

 2000-2005

39 (37 %)

90 (28 %)

 

7 (39 %)

4 (20 %)

5 (17 %)

19 (32 %)

8 (17 %)

9 (28 %)

 2006-2011

66 (63 %)

230 (72 %)

0.08

11 (61 %)

16 (80 %)

24 (83 %)

41 (68 %)

39 (83 %)

23 (72 %)

Age (years)

         

 ≤50 years

80 (76 %)

101 (32 %)

 

13 (72 %)

15 (75 %)

5 (17 %)

17 (28 %)

1 (2 %)

10 (31 %)

 >50 years

25 (24 %

219 (68 %)

<0.01

5 (28 %)

5 (25 %)

24 (83 %)

43 (72 %)

46 (98 %)

22 (69 %)

Male

81 (77 %)

255 (80 %)

0.58

14 (78 %)

19 (95 %)

29 (100 %)

52 (87 %)

47 (100 %)

23 (72 %)

Black race

89 (85 %)

280 (88 %)

0.04

17 (94 %)

18 (90 %)

24 (83 %)

55 (92 %)

44 (94 %)

31 (97 %)

Smoking

         

 Current/Former

75 (71 %)

284 (89 %)

 

15 (83 %)

18 (90 %)

27 (93 %)

59 (98 %)

43 (91 %)

30 (94 %)

 Never

30 (29 %)

36 (11 %)

<0.01

3 (17 %)

2 (10 %)

2 (7 %)

1 (2 %)

4 (9 %)

2 (6 %)

Alcohol

         

 Current/Former

37 (35 %)

188 (59 %)

 

9 (50 %)

6 (30 %)

26 (90 %)

40 (67 %)

33 (70 %)

26 (81 %)

 Never

68 (65 %)

132 (41 %)

<0.01

9 (50 %)

14 (70 %)

3 (10 %)

20 (33 %)

14 (30 %)

6 (19 %)

Injection drug use

         

 Current/Former

43 (41 %)

165 (52 %)

 

7 (39 %)

8 (40 %)

20 (69 %)

32 (53 %)

19 (40 %)

21 (66 %)

 Never

62 (59 %)

155 (48 %)

0.06

11 (61 %)

12 (60 %)

9 (31 %)

28 (47 %)

28 (60 %)

11 (34 %)

HIV Transmission

         

 IDU

38 (36 %)

145 (45 %)

 

4 22 %)

6 (30 %)

18 (62 %)

28 (47 %)

19 (40 %)

22 (69 %)

 Heterosexual

33 (31 %)

104 (33 %)

 

7 (39 %)

1 (5 %)

5 (17 %)

24 (40 %)

19 (40 %)

9 (28 %)

 MSM

29 (28 %)

50 (16 %)

 

6 (33 %)

11 (55 %)

5 (17 %)

6 (10 %)

5 (11 %)

0 (0 %)

 Transfusion

0 (0 %)

3 (1 %)

 

0 (0 %)

0 (0 %)

0 (0 %)

1 (2 %)

0 (0 %)

0 (0 %)

 Unknown

5 (5 %)

18 (6 %)

0.07

1 (6 %)

2 (10 %)

1 (3 %)

1 (2 %)

4 (9 %)

1 (3 %)

Hepatitis C

42 (40 %)

166 (52 %)

0.03

5 (28 %)

9 (45 %)

22 (76 %)

28 (47 %)

27 (57 %)

22 (69 %)

HIV duration (years)b

6.4 (1.9-12.2)

11.0 (5.6, 15.3)

<0.01

6.3 (4.1, 14.2)

14.0 (8.4, 16.4)

13.6 (7.0, 15.0)

11.4 (5.6, 15.7)

10.8 (5.3, 14.7)

14.2 (7.8, 19.0)

CD4 cell countc

         

 ≤200

37 (38 %)

197 (68 %)

 

6 (33 %)

9 (53 %)

17 (68 %)

32 (60 %)

36 (80 %)

15 (56 %)

 >200

48 (50 %)

65 (22 %)

 

10 (56 %)

6 (35 %)

5 (20 %)

15 (28 %)

4 (9 %)

8 (30 %)

 Unknown

12 (12 %)

28 (10 %)

<0.01

2 (11 %)

2 (12 %)

3 (12 %)

6 (11 %)

5 (11 %)

4 (15 %)

Average no. of HIV RNA VL per patient

6

15

<0.01

10

15

14

13

21

15

Log10 VL (copies/ml)c

4.5 (2.9-5.1)

1.7 (1.0, 3.9)

<0.01

3.0 (1.0, 4.4)

1.0 (1.0, 2.0)

1.9 (1.0, 4.4)

2.9 (1.0, 4.4)

1.0 (1.0, 2.2)

1.0 (1.0, 3.7)

HIV RNA VL suppression ≤400c

23 (34 %)

182 (63 %)

<0.01

9 (50 %)

13 (76 %)

13 (52 %)

25 (47 %)

34 (76 %)

17 (63 %)

ART at diagnosis

34 (32 %)

187 (58 %)

<0.01

6 (33 %)

15 (75 %)

13 (45 %)

31 (52 %)

39 (83 %)

17 (53 %)

  1. *P value is for comparison of ADCs vs. NADCs
  2. aOropharyngeal cancers typically include both human papillomavirus-related and -unrelated cancers
  3. bMissing HIV duration data: NADC's (2), Lung (1)
  4. cN = 290 NADC's with measurements taken within one year before cancer diagnosis. Missing data by cancer individual cancers: Hodgkin (0), Anal (3), Liver (4), Lung (7), Prostate (2), Oral (5)
  5. ADCs AIDS-defining cancers, ART antiretroviral therapy, IDU injection drug use, NADCs non-AIDS-defining cancers, VL viral load